We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.37 | -0.75% | 48.96 | 48.92 | 48.95 | 1,569 | 09:51:20 |
From May 2019 to May 2024
Alnylam Pharmaceuticals Inc.'s (ALNY) stock rose 5.9% premarket Friday after the company said the U.S. Food and Drug Administration lifted its clinical hold on studies with Alnylam's hemophilia treatment, fitusiran. Alnylam and the FDA had previously reached an agreement to mitigate risk during studies. Alnylam is working with Sanofi Genzyme, the specialty care unit of Sanofi SA (SAN.FR), on the treatment. Sanofi shares are down 1% Friday. (cara.lombardo@wsj.com; @CaraRLombardo)
(END) Dow Jones Newswires
December 15, 2017 07:46 ET (12:46 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
